MX2017010945A - Preparacion solida. - Google Patents

Preparacion solida.

Info

Publication number
MX2017010945A
MX2017010945A MX2017010945A MX2017010945A MX2017010945A MX 2017010945 A MX2017010945 A MX 2017010945A MX 2017010945 A MX2017010945 A MX 2017010945A MX 2017010945 A MX2017010945 A MX 2017010945A MX 2017010945 A MX2017010945 A MX 2017010945A
Authority
MX
Mexico
Prior art keywords
compound
solid preparation
stabilizing
formulating
fat
Prior art date
Application number
MX2017010945A
Other languages
English (en)
Inventor
Hoshina Wataru
Yamane Ikuro
Nomura Yukihiro
Nishimoto Yutaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56789547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017010945(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2017010945A publication Critical patent/MX2017010945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan: un preparado solido que mejora la estabilidad de la N-(4-(1-(2,6-difluorobencil)-5-((dimetilamino)metil)-3-(6-metox i-3-piridazinil)-,4-dioxo-1,2,3,4-tetrahidrotieno [2,3-d] pirimidin-6-i1) fenil) -N´- metoxiurea y una sal de esta que están presentes en el preparado solido; y un método para estabilizar el compuesto en el preparado sólido. Un comprimido que contiene el compuesto en una cantidad igual a al menos un 25% en masa; un preparado solido que contiene (1) el compuesto y (2) una sustancia grasa y oleosa que tiene un punto de fusión bajo seleccionada entre polietilenglicol, monoestearato de glicerilo y citrato de trietilo; un método para estabilizar el compuesto presente en el comprimido y que se caracteriza por formular el compuesto en una cantidad igual a al menos un 25% en masa; y un método para estabilizar el compuesto y que se caracteriza por formular una sustancia grasa y oleosa que tiene un punto de fusión bajo seleccionada entre polietilenglicol, monoestearato de glicerilo y citrato de trietilo en un preparado solido que contiene el compuesto.
MX2017010945A 2015-02-26 2016-02-25 Preparacion solida. MX2017010945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015037462 2015-02-26
PCT/JP2016/055540 WO2016136849A1 (ja) 2015-02-26 2016-02-25 固形製剤

Publications (1)

Publication Number Publication Date
MX2017010945A true MX2017010945A (es) 2018-07-06

Family

ID=56789547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010945A MX2017010945A (es) 2015-02-26 2016-02-25 Preparacion solida.

Country Status (23)

Country Link
US (2) US10350170B2 (es)
EP (2) EP3263110B1 (es)
JP (1) JP6730978B2 (es)
CN (1) CN107249590A (es)
AU (1) AU2016224503B2 (es)
BR (1) BR112017018173A2 (es)
CA (1) CA2978223A1 (es)
CY (1) CY1126118T1 (es)
DK (1) DK3263110T3 (es)
ES (1) ES2950995T3 (es)
FI (1) FI3263110T3 (es)
HR (1) HRP20230613T1 (es)
HU (1) HUE062269T2 (es)
IL (1) IL254132B (es)
LT (1) LT3263110T (es)
MX (1) MX2017010945A (es)
MY (1) MY180680A (es)
PL (1) PL3263110T3 (es)
PT (1) PT3263110T (es)
RS (1) RS64377B1 (es)
SI (1) SI3263110T1 (es)
TW (1) TWI744224B (es)
WO (1) WO2016136849A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2900675T (lt) 2012-09-28 2019-05-27 Takeda Pharmaceutical Company Limited Tienopirimidino darinių gamybos būdas
JP7062673B2 (ja) * 2016-09-30 2022-05-06 ミオバント サイエンシズ ゲーエムベーハー 前立腺がんの治療
CN110312512B (zh) 2016-09-30 2023-05-09 梦欧文科学有限责任公司 用于治疗子宫肌瘤和子宫内膜异位症的方法
US11306104B2 (en) 2018-03-14 2022-04-19 Teva Pharmaceuticals International Gmbh Solid state forms of Relugolix
JP2022542159A (ja) 2019-08-02 2022-09-29 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 固体形態レルゴリクス（Ｒｅｌｕｇｏｌｉｘ）
WO2021230308A1 (ja) 2020-05-15 2021-11-18 塩野義製薬株式会社 不純物の生成を抑制した医薬組成物
EP4157227A1 (en) 2020-05-29 2023-04-05 Myovant Sciences GmbH Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN115671069A (zh) * 2022-11-24 2023-02-03 北京鑫开元医药科技有限公司 一种瑞卢戈利片剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
FR2710637B1 (fr) * 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
JP3854648B2 (ja) 1994-04-19 2006-12-06 武田薬品工業株式会社 縮合チオフェン誘導体、その製造法及び用途
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
JP5072166B2 (ja) 2002-01-30 2012-11-14 武田薬品工業株式会社 チエノピリミジン化合物、その製造法および用途
MY135609A (en) * 2002-02-26 2008-05-30 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
JP4039574B2 (ja) 2003-01-29 2008-01-30 武田薬品工業株式会社 チエノピリミジン化合物およびその用途
JP2006035365A (ja) * 2004-07-26 2006-02-09 Hitachi Koki Co Ltd 携帯用切断工具
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
JP2015037462A (ja) 2012-06-01 2015-02-26 株式会社コナミデジタルエンタテインメント ゲーム装置、ゲーム方法、及びプログラム
LT2900675T (lt) 2012-09-28 2019-05-27 Takeda Pharmaceutical Company Limited Tienopirimidino darinių gamybos būdas
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
FI3263110T3 (fi) 2023-07-25
CY1126118T1 (el) 2023-11-15
IL254132B (en) 2020-02-27
EP4233847A1 (en) 2023-08-30
EP3263110A1 (en) 2018-01-03
NZ735026A (en) 2021-09-24
HUE062269T2 (hu) 2023-10-28
EP3263110A4 (en) 2018-11-07
SI3263110T1 (sl) 2023-09-29
CA2978223A1 (en) 2016-09-01
WO2016136849A1 (ja) 2016-09-01
DK3263110T3 (da) 2023-07-31
AU2016224503A1 (en) 2017-09-14
US20200000730A1 (en) 2020-01-02
US10350170B2 (en) 2019-07-16
RS64377B1 (sr) 2023-08-31
EP3263110B1 (en) 2023-05-10
LT3263110T (lt) 2023-07-10
PL3263110T3 (pl) 2023-11-06
JP6730978B2 (ja) 2020-07-29
IL254132A0 (en) 2017-10-31
PT3263110T (pt) 2023-08-01
HRP20230613T1 (hr) 2023-09-29
US20180036250A1 (en) 2018-02-08
CN107249590A (zh) 2017-10-13
ES2950995T3 (es) 2023-10-17
BR112017018173A2 (pt) 2018-04-10
AU2016224503B2 (en) 2021-07-08
JPWO2016136849A1 (ja) 2017-12-07
TW201639575A (zh) 2016-11-16
MY180680A (en) 2020-12-06
TWI744224B (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
MX2017010945A (es) Preparacion solida.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
WO2015132799A3 (en) Heterocyclic compounds
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
UA122552C2 (uk) Композиція та спосіб для боротьби з захворюваннями, спричиненими фітопатогенами
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
EA201691538A1 (ru) Способ получения солей вортиоксетина
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
PH12016501328B1 (en) Pharmaceutical composition containing pyridylaminoacetic acid compound
MX2017002967A (es) Composicion farmaceutica novedosa que contiene derivado de acido hidroxamico o sal del mismo.
MX2016009058A (es) Compuesto de acido piridilaminoacetico y composicion farmaceutica que contiene aceite de ricino polioxietileno.
ES2530423A2 (es) Nuevas formas solidas de inhibidores de la fosfodiesterasa tipo 5
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
PH12017502252B1 (en) Stable pharmaceutical composition for oral administration
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
IL274715A (en) A method for producing (3s)-3-(4-chloro-3-{[(2s,3r)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3- Cyclopropylpropanoic acid and its crystalline form for use as a pharmaceutical ingredient
IN2015DN03734A (es)
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
MX2017013788A (es) Composicion farmaceutica estabilizada.
MX2016008729A (es) Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
PH12018501314A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound

Legal Events

Date Code Title Description
FG Grant or registration